Name (Synonyms) | Correlation |
---|
There is one clinical trial.
CovidSurg-Cancer is an international, multicentre, observational cohort study designed to evaluate the 30-day COVID-19 infection rates in elective cancer surgery during the COVID-19 pandemic. Centres can elect to include one or more cancer types in the study, in any combination, depending on local expertise and capacity. During the pilot study, investigators should enrol patients with confirmed diagnoses of: - Colorectal cancer - Oesophagogastric cancer As a rapid response study to the COVID-19 pandemic, included cancer types will evolve throughout the course of the CovidSurg-Cancer study period, for example, to include breast, liver, pancreatic, gynaecological, urological cancers, or sarcomas.
Description: Frequency of COVID-19 infection within 30 days
Measure: 30-day postoperative COVID-19 infection rate Time: 30 daysDescription: Number of deaths at 30-days post surgery
Measure: 30-day postoperative mortality rate Time: 30-daysDescription: Critical care utilisation in high-risk cancer surgery patients
Measure: Postoperative critical care utilisation rate in high-risk cancer surgery patients. Time: 30-daysDescription: Number of patients with a delay of more than 4 weeks from the decision taken for surgery to the date of surgery
Measure: Proportion of patients with delay of greater than 4 weeks from decision for surgery to date of surgery Time: More than 4 weeks from decision dateDescription: Number of non-operated patients with progression to incurable disease by 3-months after decision for surgery
Measure: Proportion of non-operated patients with progression to incurable disease by 3-months after decision for surgery Time: Up to 3-months